Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Flurbiprofen
Drug ID BADD_D00941
Description Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
Indications and Usage Flurbiprofen tablets are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Topical ophthalmic formulations may be used pre-operatively to prevent intraoperative miosis.
Marketing Status Prescription; Discontinued
ATC Code M01AE09; M02AA19; R02AX01; S01BC04
DrugBank ID DB00712
KEGG ID D00330
MeSH ID D005480
PubChem ID 3394
TTD Drug ID D0A1PX
NDC Product Code 63629-8808; 45865-918; 66577-029; 62756-510; 43063-992; 63275-9913; 38779-2739; 68071-4436; 51927-0008; 68788-7341; 55545-0405; 63629-8338; 22568-1093; 68071-2480; 0395-8053; 38779-0362; 51552-0818; 0093-0711; 51686-0004; 49452-3178; 62991-3064; 51927-0219; 61891-001; 17511-123
Synonyms Flurbiprofen | 2-Fluoro-alpha-methyl-(1,1'-biphenyl)-4-acetic Acid | Flubiprofen | Fluriproben | Dobrofen | E-7869 | E 7869 | E7869 | Nu-Flurbiprofen | Nu Flurbiprofen | Ocufen | ratio-Flurbiprofen | ratio Flurbiprofen | Strefen | Flugalin | Flurbiprofen Sodium | Froben | Neo Artrol | Novo-Flurprofen | Novo Flurprofen | Ansaid | Apo-Flurbiprofen | Apo Flurbiprofen | BTS-18322 | BTS 18322 | BTS18322 | Cebutid | Froben SR | Ocuflur
Chemical Information
Molecular Formula C15H13FO2
CAS Registry Number 5104-49-4
SMILES CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Mitochondrial toxicityCytochrome P450 2C11P08683Not Available26099455
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.002--Not Available
Inflammatory bowel disease07.08.01.016--Not Available
Influenza11.05.03.001; 22.07.02.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Iron deficiency14.13.02.002--Not Available
Iron deficiency anaemia14.13.02.001; 01.03.01.002--Not Available
Jaundice09.01.01.004; 01.06.04.004; 23.03.03.030--Not Available
Jaundice cholestatic09.01.01.005--Not Available
Keratitis06.04.02.002--
Laryngitis22.07.03.001; 11.01.13.001--
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Libido decreased19.08.03.001; 21.03.02.005--
Lip oedema23.04.01.006; 07.05.04.004; 10.01.05.0040.009698%Not Available
Loss of consciousness17.02.04.004--Not Available
Lung disorder22.02.07.001--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
Melaena07.12.02.004; 24.07.02.013--Not Available
Meningitis17.06.03.001; 11.01.03.001--
Meningitis aseptic11.01.03.002; 17.06.03.002--Not Available
Menstrual disorder21.01.01.004--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mood swings19.04.03.001--Not Available
Muscle twitching15.05.03.005--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Myocardial infarction24.04.04.009; 02.02.02.007--
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages